SCPS (Scopus BioPharma) 14-Day RSI: 52.55 (As of Jul. 02, 2026)


What is Scopus BioPharma 14-Day RSI?

Scopus BioPharma SCPS -16.67% 14-Day RSI is 52.55 as of Jul. 02, 2026.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2026-07-02), Scopus BioPharma's 14-Day RSI is 52.55.

The industry rank for Scopus BioPharma's 14-Day RSI or its related term are showing as below:

SCPS's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 48.55 vs SCPS: 52.55

Scopus BioPharma  (OTCPK:SCPS) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

Scopus BioPharma 14-Day RSI Related Terms

SCPS vs AMPE, DRMA, SPRC: 14-Day RSI Comparison

For the Biotechnology subindustry, Scopus BioPharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scopus BioPharma 14-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's 14-Day RSI falls into.


Scopus BioPharma  (OTCPK:SCPS) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100–[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 14-Day RSI →
What does a 14-Day RSI of 52.55 mean?
Scopus BioPharma (SCPS) has a 14-Day RSI of 52.55 as of Jul. 02, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Scopus BioPharma and its competitors.
Is Scopus BioPharma's 14-Day RSI too high?
Scopus BioPharma's current 14-Day RSI is 52.55. The Biotechnology industry median 14-Day RSI is 48.55. Scopus BioPharma's value of 52.55 is 8.2% above this industry median.
How does Scopus BioPharma's 14-Day RSI compare to AMPE and DRMA?
Scopus BioPharma's 14-Day RSI of 52.55 can be compared against companies in the Biotechnology industry. The industry median 14-Day RSI is 48.55. Scopus BioPharma's value of 52.55 is 8.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.55, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scopus BioPharma's current 14-Day RSI of 52.55 is 8.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Scopus BioPharma and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scopus BioPharma's current 14-Day RSI is 52.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scopus BioPharma stock overvalued right now?
Scopus BioPharma (SCPS) has a current 14-Day RSI of 52.55. The current 14-Day RSI is 52.55 and 8.2% above the Biotechnology industry median of 48.55. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Scopus BioPharma (SCPS), the current 14-Day RSI is 52.55 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scopus BioPharma Business Description

Address 420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.